As of Jul 6, 2025, Dexcom's P/S ratio stood at 8.46, a 6.28% change from the 7.96 P/S ratio recorded in the previous year.

The Dexcom P/S history

Dexcom Aktienanalyse

What does Dexcom do?

Dexcom Inc is a US medical technology company specializing in the development and manufacturing of medical devices for monitoring blood sugar levels in diabetes. The company was founded in 1999 by Scott Glenn and John Burd and is headquartered in San Diego, California. Dexcom's history began with the development of a continuous glucose sensor by Scott Glenn, who himself has Type 1 diabetes. In 2006, the company received approval from the US Food and Drug Administration (FDA) for its first continuous glucose sensor, which was marketed as the "Dexcom STS". Since then, the company has developed and launched numerous other products. Dexcom's business model is based on offering solutions to improve the quality of life for people with diabetes through the use of modern technology. The company primarily offers continuous glucose monitoring (CGM) systems, which continuously and in real-time monitor blood sugar levels to optimize insulin therapy and avoid hypoglycemia. Dexcom's goal is to make the daily management of diabetes easier and safer, and to improve the quality of life for those affected. Currently, Dexcom offers two CGM systems: the "Dexcom G6" and the "Dexcom G7". The G6 system has been on the market since 2018 and has been used by over one million people worldwide. It consists of three components: a sensor, a transmitter, and a receiver. The sensor is placed under the skin and continuously measures glucose levels in the tissue. The transmitter sends the measurements to the receiver, which displays the current blood sugar level to the patient. Another option is to connect the system to a smartphone app. The G7 system is still in development and is expected to be launched in 2021. It promises even easier handling and longer battery life. Dexcom has also formed partnerships with other companies, such as insulin pump manufacturers like Tandem Diabetes Care, to enable integration of CGM systems into these devices and enable automated insulin therapy. Currently, Dexcom employs over 3,800 people worldwide and operates in over 50 countries. The company has experienced strong growth in recent years and has steadily increased its revenues. In 2019, Dexcom's revenue was approximately $1.5 billion, representing a 43% increase from the previous year. Overall, Dexcom has established itself as a leading provider in the field of continuous glucose monitoring with its innovative products and focus on improving the quality of life for people with diabetes. The company has successfully made the daily lives of millions of individuals worldwide easier and has become an important partner in diabetes care. Dexcom ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Dexcom's P/S Ratio

Dexcom's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Dexcom's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Dexcom's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Dexcom’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Dexcom stock

What is the price-to-earnings ratio of Dexcom?

The price-earnings ratio of Dexcom is currently 8.46.

How has the price-earnings ratio of Dexcom changed compared to last year?

The price-to-earnings ratio of Dexcom has increased by 6.28% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Dexcom high compared to other companies?

Yes, the price-to-earnings ratio of Dexcom is high compared to other companies.

How does an increase in the price-earnings ratio of Dexcom affect the company?

An increase in the price-earnings ratio of Dexcom would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Dexcom affect the company?

A decrease in the price-earnings ratio of Dexcom would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Dexcom?

Some factors that influence the price-earnings ratio of Dexcom are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Dexcom pay?

Over the past 12 months, Dexcom paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dexcom is expected to pay a dividend of 0 USD.

What is the dividend yield of Dexcom?

The current dividend yield of Dexcom is .

When does Dexcom pay dividends?

Dexcom pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Dexcom?

Dexcom paid dividends every year for the past 0 years.

What is the dividend of Dexcom?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Dexcom located?

Dexcom is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dexcom kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dexcom from 7/6/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/6/2025.

When did Dexcom pay the last dividend?

The last dividend was paid out on 7/6/2025.

What was the dividend of Dexcom in the year 2024?

In the year 2024, Dexcom distributed 0 USD as dividends.

In which currency does Dexcom pay out the dividend?

The dividends of Dexcom are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Dexcom stock can be added to a savings plan with the following providers: Trade Republic and Consorsbank

Andere Kennzahlen von Dexcom

Our stock analysis for Dexcom Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dexcom Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.